HEPA Hepion Pharmaceuticals Inc.

1.61
-0.01  -1%
Previous Close 1.62
Open 1.71
Price To Book 0.67
Market Cap 9,779,336
Shares 6,074,122
Volume 406,867
Short Ratio
Av. Daily Volume 826,834
Stock charts supplied by TradingView

NewsSee all news

  1. Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study

    EDISON, NJ / ACCESSWIRE / March 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, ", Hepion", )), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease

  2. Anti-Fibrotic Activity of Hepion Pharmaceuticals' CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases

    CRV431 Decreases Collagen and Fibronectin Production from Multiple Cell TypesEDISON, NJ / ACCESSWIRE / February 19, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the

  3. Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

    EDISON, NJ / ACCESSWIRE / February 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  4. Hepion's NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study

    EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the

  5. Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference

    EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial discontinued - November 2017.
Valnivudine - FV-100
Shingles
Phase 2 trial to be initiated 2H 2020.
CRV431
Non-alcoholic steatohepatitis

Latest News

  1. Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study

    EDISON, NJ / ACCESSWIRE / March 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, ", Hepion", )), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease

  2. Anti-Fibrotic Activity of Hepion Pharmaceuticals' CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases

    CRV431 Decreases Collagen and Fibronectin Production from Multiple Cell TypesEDISON, NJ / ACCESSWIRE / February 19, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the

  3. Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

    EDISON, NJ / ACCESSWIRE / February 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  4. Hepion's NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study

    EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the

  5. Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference

    EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  6. Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs

    EDISON, NJ / ACCESSWIRE / January 6, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  7. Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

    EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  8. Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019

    EDISON, NJ / ACCESSWIRE / December 9, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  9. Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

    University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion

  10. Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  11. Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th

    CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual

  12. Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease

    EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  13. Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019

    EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  14. Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH

    CRV431 has Potently Reduced Fibrosis in all Experimental Models Tested To DateEDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the

  15. World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director

    EDISON, NJ / ACCESSWIRE / October 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

  16. Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions

    Collectively, Company's Senior Management Team Has More Than 100 Years of Cyclophilin ExperienceEDISON, NJ / ACCESSWIRE / October 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company